

## Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

Jon Bjoern<sup>1,2</sup>, Rikke Lyngaa<sup>3,1</sup>, Rikke Andersen<sup>1,2</sup>, Lisbet Rosenkrantz Hölmich<sup>4</sup>, Sine Reker Hadrup<sup>3,1</sup>, Marco Donia<sup>1,2</sup> and Inge Marie Svane<sup>1,2</sup>

<sup>1</sup> Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

<sup>2</sup> Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

<sup>3</sup> Section for Immunology and Vaccinology, Technical University of Denmark, Copenhagen, Denmark

<sup>4</sup> Department of Plastic Surgery, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

**Published:** November 09, 2018

**Copyright:** Bjoern et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The correct name of the 4th author is as follows:

**Lisbet Rosenkrantz Hölmich**

Original article: Oncotarget. 2017; 8:27062-27074. <https://doi.org/10.18632/oncotarget.16003>